深圳微芯生物科技股份有限公司关于与Nizhpharm签署许可及分销协议的公告

Agreement Overview - Shenzhen MicuRx Biotech Co., Ltd. has signed a licensing and distribution agreement with Nizhny Novgorod Chemical Pharmaceutical Plant (Nizhpharm) for the product Chidamide [1] - Nizhpharm will have exclusive rights for research, registration, and commercialization of Chidamide in several countries including Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Mongolia, Russia, Tajikistan, Uzbekistan, Georgia, and Turkmenistan [1][5] Counterparty Information - Nizhpharm is one of the leading pharmaceutical companies in the Russian Federation, established in 1919, focusing on unmet medical needs and has a modern production base compliant with GMP standards [3] Product Information - Chidamide (brand name "Epidaza") is the world's first subtype-selective histone deacetylase (HDAC) inhibitor, approved for multiple indications in China, Japan, and Taiwan [4] Key Terms of the Agreement - Nizhpharm will be responsible for the development, registration, repackaging, transportation, and commercialization of Chidamide in the authorized regions [6] - The agreement includes an initial payment of 10 million RMB and additional milestone payments totaling 10 million RMB for local registration [6] - The agreement will last for 10 years from the first market approval of the product in the licensed area [6] Impact on the Company - This licensing agreement is expected to accelerate the global development and commercialization of Chidamide, enhancing the company's brand value and international influence [8]